Last reviewed · How we verify

Angiotensin Ii (ANGIOTENSIN)

La Jolla Pharma · FDA-approved active Recombinant protein Quality 46/100

Angiotensin II works by binding to its receptor, triggering a cascade of signals that ultimately lead to the constriction of blood vessels.

Angiotensin II, marketed by La Jolla Pharma, is an approved treatment for septic or other distributive shock, leveraging its mechanism of action through receptor binding to constrict blood vessels. The drug's key strength lies in its unique mechanism, which addresses a critical unmet need in shock management. The primary risk is the key composition patent expiry in 2028, which could introduce generic competition and impact revenue.

At a glance

Generic nameANGIOTENSIN
SponsorLa Jolla Pharma
Drug classVasoconstrictor [EPC]
ModalityRecombinant protein
Therapeutic areaHematology
PhaseFDA-approved
First approval2025

Mechanism of action

Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein coupled-angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca 2+ /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: